Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3909755 | 0.91 | PTPN1 (0.46) | PTPN1 | |
| SCHEMBL3911855 | 0.90 | MAP4K4 (0.37) | PTPN1RXFP1TP53LMNAALDH1A1 | |
| SCHEMBL3906664 | 0.90 | MAP4K4 (0.37) | PTPN1RXFP1TP53LMNAALDH1A1 | |
| SCHEMBL3906841 | 0.88 | PTPN1 (0.38) | PTPN1ALOX5APFEN1ALDH1A1NR1H4 | |
| SCHEMBL3906898 | 0.88 | PTPN1 (0.34) | PTPN1ALOX5APFEN1NR1H4CACNA1B | |
| SCHEMBL3907660 | 0.86 | PTPN1 (0.37) | PTPN1ALDH1A1NR1H4CACNA1B | |
| SCHEMBL3904730 | 0.85 | PTPN1 (0.38) | PTPN1RXFP1TP53LMNAGAA | |
| SCHEMBL3908053 | 0.83 | NR1H4 (0.37) | PTPN1NR1H4CACNA1BCTSK | |
| SCHEMBL3904787 | 0.83 | PTPN1 (0.35) | PTPN1ALDH1A1NR1H4CACNA1BCTSK | |
| SCHEMBL3909895 | 0.82 | PTPN1 (0.39) | PTPN1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | PTPN1 11/4885RXFP1 4103/4885TP53 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.